APEIRON Biologics AG

@apeironbio

Apeiron, based in Vienna, Austria, is focused on the development of novel cancer Immunotherapies.

Vienna
Vrijeme pridruživanja: srpanj 2011.

Tweetovi

Blokirali ste korisnika/cu @apeironbio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @apeironbio

  1. 10. sij

    Peter Llewellyn-Davies (CEO) & Dr. Romana Gugenberger are looking forward to introduce you to , a new APEIRON Biologics spin-off, and their efforts to fight with in San Francisco at and .

    Poništi
  2. 30. ruj 2019.
    Poništi
  3. 30. ruj 2019.

    We are pleased to participate in the Congress 2019 in Barcelona! Poster: "1231P - Master Checkpoint Cbl-b Inhibition: Anti-tumor Efficacy in a Murine Colorectal Cancer Model Following siRNA-based Cell Therapy" Poster Display Session 3, 12pm-1pm, today; Poster Area Hall 4

    Poništi
  4. proslijedio/la je Tweet
    23. ruj 2019.

    : all released abstracts now available online on OncologyPRO 📣📣 All are open access & searchable by title/author

    Poništi
  5. 17. ruj 2019.

    APEIRON Biologics AG presents in two important scientific meetings in September 2019:

    Poništi
  6. 22. srp 2019.

    👏 Everything you do with passion will succeed.

    Poništi
  7. 22. srp 2019.

    A story like this makes us particularly proud to be the first Austrian company to launch Qarziba, an drug, together with Professor Holger Lodge.

    Poništi
  8. 20. svi 2019.

    APEIRON Biologics is one of the presenting companies at in Barcelona. CEO reports this afternoon to the interested audience about the current developments at .

    Poništi
  9. proslijedio/la je Tweet
    20. svi 2019.

    20th Europe: Today, Europe's partnering conference for dealmakers and investor-validated life science companies opened its doors in to discuss , . Check out the event's program

    Poništi
  10. 19. svi 2019.

    A warm welcome to the guests of Bio€quity 2019 in Barcelona!

    Poništi
  11. 17. svi 2019.

    Our CEO Peter Llewellyn-Davies will attend Europe in Barcelona and present the latest developments of APEIRON Biologics. We look forward to meeting you there.

    Poništi
  12. 15. svi 2019.

    A nice get-together! 🇺🇸🇦🇹Thanks to Austrian Marshall Plan Foundation and Advantage Austria ⁦⁩ for the great organisation.

    Poništi
  13. 9. svi 2019.

    Meet the CEO of APEIRON Biologics Peter Llewellyn-Davies at 2019 and learn more about the company at first hand.

    Poništi
  14. proslijedio/la je Tweet
    27. tra 2019.

    Great list, love the bonus episode - Top 10 Biotech Podcasts You Should Listen to this Spring via

    Poništi
  15. 7. svi 2019.

    It was nice to be part of the Swiss Biotech Day 2019! See you next time!

    Poništi
  16. 7. svi 2019.

    Our CMO & CSO Anderson Gaweco, M.D., PhD, is currently speaking in Panel 2 "Cell-based Therapeutics" at Swiss Biotech Day 2019: Master Checkpoint Cbl-b Inhibition - Ambulatory siRNA-Based Autologous Cell Therapy for Cancer

    Poništi
  17. 24. tra 2019.

    APEIRON would like to extend their sincerest thanks to the Oncology Leadership at Cancer Center in Dallas, TX.

    Poništi
  18. proslijedio/la je Tweet
    18. tra 2019.

    One of my favorite biotech keynote - What Does the Future Hold for European Biotech? Insights from Evotec’s CEO Werner Lanthaler

    Poništi
  19. 18. tra 2019.

    Please join our Chief Medical Officer & Chief Scientific Officer Anderson Gaweco, MD, PhD, who will speak at the invitation of Daniel D. Von Hoff, MD, FACP, FASCO, FAACR and Carlos Becerra at the Research Institute on "Master Checkpoint Cbl-b Inhibition"

    Poništi
  20. 13. tra 2019.

    The scientific program of the in with an international faculty has focused on the most relevant topics of of . Congratulations to the Conference Presidents and

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·